Renal Failure with the Use of Zoledronic Acid

doi:10.1056/NEJM200310233491721

Volume 349:1676-1679		October 23, 2003		Number 17

Renal Failure with the Use of Zoledronic Acid

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

To the Editor: Zoledronic acid (Zometa, Novartis Pharmaceuticals)is a potent bisphosphonate that inhibits bone resorption. Intrials of treatment for bone metastases, 9 to 15 percent ofthe patients who received 4 mg of zoledronic acid over a 15-minuteperiod had renal deterioration, defined by elevations in theserum creatinine level.¹^,² With marketed use of the drug, renaldeterioration progressing to renal failure and dialysis hasbeen reported. Although the causes of renal deterioration aremultifactorial, acute tubular necrosis has been described asa potential mechanism associated with zoledronic acid.³

We identified 72 cases in the Food and Drug . . . [Full Text of this Article]

This article has been cited by other articles:

LeGrand, S. B., Leskuski, D., Zama, I. (2008). Narrative Review: Furosemide for Hypercalcemia: An Unproven yet Common Practice. ANN INTERN MED 149: 259-263 [Abstract] [Full Text]
von Moos, R., Caspar, C. B., Thurlimann, B., Angst, R., Inauen, R., Greil, R., Bergstrom, B., Schmieding, K., Pecherstorfer, M. (2008). Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol 19: 1266-1270 [Abstract] [Full Text]
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G. N., Jonat, W., Lipton, A., Monnier, A., Paterson, A. H. G., Rizzoli, R., Saad, F., Thurlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432 [Abstract] [Full Text]
Brown, J. E., Ellis, S. P., Lester, J. E., Gutcher, S., Khanna, T., Purohit, O.-P., McCloskey, E., Coleman, R. E. (2007). Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clin. Cancer Res. 13: 5406-5410 [Abstract] [Full Text]
de Nijs, R. N.J., Westgeest, A. A.A., Poole, K. E.S., Kaptoge, S., Reeve, J., Karam, R., Camm, J., McClung, M., Najib, M. A., Aziz, I., Chang, J. T., Black, D., Eriksen, E., Sellmeyer, D., Compston, J. (2007). Yearly zoledronic acid in postmenopausal osteoporosis.. NEJM 357: 711-712 [Full Text]
Bergner, R., Henrich, D. M., Hoffmann, M., Honecker, A., Mikus, G., Nauth, B., Nagel, D., Uppenkamp, M. (2007). Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function. J Clin Pharmacol 47: 942-950 [Abstract] [Full Text]
Kyle, R. A., Yee, G. C., Somerfield, M. R., Flynn, P. J., Halabi, S., Jagannath, S., Orlowski, R. Z., Roodman, D. G., Twilde, P., Anderson, K. (2007). American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. JCO 25: 2464-2472 [Abstract] [Full Text]
Compston, J. (2007). Treatments for Osteoporosis -- Looking beyond the HORIZON. NEJM 356: 1878-1880 [Full Text]
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., Smith, M. R. (2007). Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men With Prostate Cancer. JCO 25: 1038-1042 [Abstract] [Full Text]
Aguiar Bujanda, D, Bohn Sarmiento, U, Cabrera Suarez, M., Aguiar Morales, J (2007). Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18: 556-560 [Abstract] [Full Text]
Gridelli, C. (2007). The Use of Bisphosphonates in Elderly Cancer Patients. The Oncologist 12: 62-71 [Abstract] [Full Text]
Body, J.-J. (2006). Breast cancer: bisphosphonate therapy for metastatic bone disease.. Clin. Cancer Res. 12: 6258s-6263s [Abstract] [Full Text]
Yeh, H. S., Berenson, J. R. (2006). Treatment for myeloma bone disease.. Clin. Cancer Res. 12: 6279s-6284s [Abstract] [Full Text]
Paterson, A. H.G. (2006). The Role of Bisphosphonates in Early Breast Cancer. The Oncologist 11: 13-19 [Abstract] [Full Text]
Cameron, D., Fallon, M., Diel, I. (2006). Ibandronate: Its Role in Metastatic Breast Cancer. The Oncologist 11: 27-33 [Abstract] [Full Text]
Tanvetyanon, T., Stiff, P. J. (2006). Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17: 897-907 [Abstract] [Full Text]
Yang, M., Burton, D. W., Geller, J., Hillegonds, D. J., Hastings, R. H., Deftos, L. J., Hoffman, R. M. (2006). The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model. Clin. Cancer Res. 12: 2602-2606 [Abstract] [Full Text]
Crawford, B. A.L., Kam, C., Pavlovic, J., Byth, K., Handelsman, D. J., Angus, P. W., McCaughan, G. W. (2006). Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.. ANN INTERN MED 144: 239-248 [Abstract] [Full Text]
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., Bekker, P. J. (2006). A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer. Clin. Cancer Res. 12: 1221-1228 [Abstract] [Full Text]
Mehrotra, B., Ruggiero, S. (2006). Bisphosphonate Complications Including Osteonecrosis of the Jaw. ASH Education Book 2006: 356-360 [Abstract] [Full Text]
Michaelson, M. D., Smith, M. R. (2005). Bisphosphonates for Treatment and Prevention of Bone Metastases. JCO 23: 8219-8224 [Abstract] [Full Text]
Body, J.-J. (2005). Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters. The Oncologist 10: 1-2 [Full Text]
Body, J.-J., Pfister, T., Bauss, F. (2005). Preclinical Perspectives on Bisphosphonate Renal Safety. The Oncologist 10: 3-7 [Abstract] [Full Text]
Jackson, G. H. (2005). Renal Safety of Ibandronate. The Oncologist 10: 14-18 [Abstract] [Full Text]
von Moos, R. (2005). Bisphosphonate Treatment Recommendations for Oncologists. The Oncologist 10: 19-24 [Abstract] [Full Text]
Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., Dunstan, C. R., Kostenuik, P. J. (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology 146: 3235-3243 [Abstract] [Full Text]
Shimada, H., Shima, H., Shimasaki, N., Yoshihara, H., Mori, T., Takahashi, T. (2005). Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol 16: 1400-1400 [Full Text]
Munier, A., Gras, V., Andrejak, M., Bernard, N., Jean-Pastor, M.-J., Gautier, S., Biour, M., Massy, Z. (2005). Zoledronic Acid and Renal Toxicity: Data from French Adverse Effect Reporting Database. The Annals of Pharmacotherapy 39: 1194-1197 [Abstract] [Full Text]
Chabner, B. A. (2005). Late Toxicities of Drugs: Bisphosphonates. The Oncologist 10: 301-303 [Full Text]
Balla, J. (2005). The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View. The Oncologist 10: 306-308 [Full Text]
Lugassy, G. (2005). "Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid": Not So Safe. The Oncologist 10: 309-310 [Full Text]
Jackson, G. (2005). Safety and Compliance of Intravenous and Oral Dosing Regimens. The Oncologist 10: 313-314 [Full Text]
Conte, P., Guarneri, V. (2005). In Response to Jackson Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens". The Oncologist 10: 315-316 [Full Text]
Diel, I. J., Bergner, R. (2005). Re: Berenson J, Hirschberg R. Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid. The Oncologist 10: 82-83 [Full Text]
Ferretti, G., Petti, M. C., Carlini, P., Zeuli, M., Picardi, A., Meloni, G., Bria, E., Papaldo, P., Fabi, A., Cognetti, F. (2004). Zoledronic acid-associated thrombotic thrombocytopenic purpura. Ann Oncol 15: 1847-1848 [Full Text]

Comments and questions? Please contact us.